SCHEMBL1421600

SCHEMBL1421600

COc1cc(OC)c2c(=O)cc(-c3ccc(OCc4ccccc4)c(OC)c3)oc2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ABCG2 Q9UNQ0 5/20 0.67
▸ MEN1 O00255 3/20 0.67
▸ KMT2A Q03164 3/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ NPC1 O15118 2/20 0.67
▸ ALDH1A1 P00352 1/20 0.67
▸ RAB9A P51151 1/20 0.67
▸ L3MBTL1 Q9Y468 1/20 0.66
▸ CYP1A1 P04798 2/20 0.64
▸ CYP1A2 P05177 2/20 0.64
▸ ABCB1 P08183 5/20 0.62
▸ PPARG P37231 3/20 0.59
▸ BCHE P06276 1/20 0.57
▸ ACHE P22303 1/20 0.57
▸ CYP1B1 Q16678 2/20 0.56
▸ MAPT P10636 2/20 0.54
▸ TP53 P04637 1/20 0.54
▸ MDM2 Q00987 1/20 0.54
▸ CYP3A4 P08684 1/20 0.54
▸ CYP2C9 P11712 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8064295 0.93 L3MBTL1 (0.71) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL1976256 0.92 MAPT (0.67) ABCG2MEN1KMT2ANPC1ALDH1A1
SCHEMBL8066758 0.92 L3MBTL1 (0.72) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL29979584 0.89 L3MBTL1 (0.79) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL24514601 0.87 ABCB1 (0.73) ABCG2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL24514598 0.86 ABCB1 (0.68) ABCG2MEN1KMT2AALDH1A1L3MBTL1
SCHEMBL7603078 0.86 L3MBTL1 (0.65) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL30376090 0.85 L3MBTL1 (0.77) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL19267888 0.85 L3MBTL1 (0.77) ABCG2MEN1KMT2AKDM4ENPC1
SCHEMBL7156543 0.85 ABCB1 (0.69) ABCG2MEN1KMT2AALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS (LU) 2011-06-16 — — US disclosed
EP-2297127-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AxoGlia Therapeutics S.A. (LU) 2011-03-23 — — EP disclosed
WO-2009130253-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES AXOGLIA THERAPEUTICS S.A. (LU) 2009-10-29 — — WO disclosed
EP-2112145-A1 Chromenone derivatives useful for the treatment of neurodegenerative diseases AxoGlia Therapeutics S.A. (LU) 2009-10-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144194-A1 CHROMENONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES PARK7, CDR2, SNCA ABCG2 1767/4885MEN1 1507/4885KMT2A 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback